Skip to content
Menu
CareerHospital
NETWORK
  • Home
  • Careers
  • by Location
  • News
  • Post
  • Specialties
Close Menu

United Therapeutics Announces FDA Acceptance of Second Resubmission of Oral Treprostinil NDA

Press Releases

SILVER SPRING, Md., Sept. 11, 2013 /PRNewswire/ — United Therapeutics Corporation (NASDAQ: UTHR) announced today that the U.S. Food and Drug Administration (FDA) has acknowledged the resubmission of the new drug application (NDA) for treprostinil diolamine extended release tablets (oral treprostinil) for the treatment of pulmonary arterial hypertension. The FDA classified the resubmission as a complete, class 2 response to its March 22, 2013 complete response letter, and set a user fee goal date of February 16, 2014.

About United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Forward-looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, statements regarding the FDA’s user fee goal date of February 16, 2014. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of September 11, 2013, and assume no obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason. [uthr-g]

SOURCE United Therapeutics Corporation

Related Posts

Press Releases

Teladoc Health to Acquire InTouch Health

Press Releases

Vivante Health Snags DebraAnn Braun as Chief Technology Officer

Press Releases

Dr. Jason Hallock Joins SOC Telemed as Chief Medical Officer

SPONSOR & POST
Feature your Brand & Jobs. Sponsor the Front Page of this site for less than $50 per month. Sponsors can be featured on the Front Page, Categories, Cities & Footer. Learn How

Featured Jobs

  • MGR- OBSERVATION CENTER 8SOUTH

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • SURG TECHNOLOGIST-CERT

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • ADM – ORTHOPEDICS 6W

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • ADM – MEDICAL ICU 10W

    • Lansing, MI
    • Sparrow Health System
    • Full Time
  • SHS-MGR CLINICAL INTEGRATION

    • Lansing, MI
    • Sparrow Health System
    • Full Time

News & Views

  • Teladoc Health to Acquire InTouch Health
  • Vivante Health Snags DebraAnn Braun as Chief Technology Officer
  • Dr. Jason Hallock Joins SOC Telemed as Chief Medical Officer
  • Change Healthcare Unveils API & Services Connection, a Marketplace to Accelerate Innovation in Healthcare
  • Gemelli Hospital on Track to Become More Digitized for Better Patient Management
Back To Top
CareerHospital
Copyright © CareerHospital.com
All Rights Reserved!
SPONSOR & POST
Feature your Brand & Jobs. Sponsor the Front Page of this site for less than $50 per month. Sponsors can be featured on the Front Page, Categories, Cities & Footer. Learn How